By Priya Mehta, PharmD, Clinical Pharmacist. Medically reviewed by Dr. Robert Yamada, MD, Board-Certified Endocrinology.
Last month a woman named Dana in Phoenix called her telehealth provider in a mild panic. She'd been on compounded tirzepatide for three weeks at 2.5 mg per week, drawing 10 units from a 2.5 mg/mL vial. Then her pharmacy shipped a refill at 5 mg/mL. She drew 10 units again out of habit. That single injection delivered 5 mg instead of 2.5 mg, double her prescribed dose. "I didn't even think to check the label," she told her provider. "The vial looked the same." She spent the next 36 hours managing nausea and regret.
Dana's mistake is one of the most common errors in compounded GLP-1 therapy. And it's entirely preventable, once you understand what 2.5 mg/mL actually means and how that number interacts with your syringe.
This guide is part of the FormBlends ultimate guide to compounded tirzepatide and the Tirzepatide Dosing & Protocols hub.
The short version
- The dosing math is simple: dose (mg) divided by concentration (mg/mL) equals volume (mL). Multiply that volume by 100 to get units on a U-100 syringe.
- The unit count changes every time the pharmacy ships a different concentration, even if your prescribed milligram dose stays the same. Read the label every time.
- Standard tirzepatide escalation from SURMOUNT-1: 2.5 mg weekly for 4 weeks, then 5 mg, with step-ups every 4 weeks as tolerated.
- Compounded tirzepatide is not FDA-approved. The FDA does not pre-review compounded medications for safety, effectiveness, or quality.
Why "2.5 mg/mL" Generates So Much Confusion
This phrase pulls roughly 1,000 monthly U.S. searches, which tells you something: people are getting vials in the mail and not finding clear answers in the box.
Here's the thing. "2.5 mg/mL" is a concentration, not a dose. It tells you how much active drug is dissolved in each milliliter of solution. It does not tell you how much to inject. That depends on your prescribed dose and the syringe you're using.
The math feels almost insultingly simple once you see it, but it trips people up because the numbers shift:
- A 2.5 mg/mL vial: to get a 2.5 mg dose, you draw 1 mL, which equals 100 units on a U-100 syringe.
- A 5 mg/mL vial: same 2.5 mg dose now requires 0.5 mL, or 50 units.
- A 10 mg/mL vial: same dose, 0.25 mL, 25 units.
The milligrams per "unit" on your syringe depend entirely on what's in the vial. A 10 mg/mL vial delivers 0.1 mg per unit. A 5 mg/mL vial delivers 0.05 mg per unit. Swap the vial, recalculate the units. Every time. No exceptions.
Starting Right: Eligibility and the First Four Weeks
The right medication for the right patient at the right dose is the single highest-impact decision in this process. Everything downstream (escalation speed, tolerability, outcomes) flows from whether the initial assessment was thorough and the medical history was honest. Shortcuts here compound badly.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Once eligibility is confirmed, the trial-validated starting point is 2.5 mg weekly for four weeks. This isn't a therapeutic dose for most people; it's an onboarding dose. The body needs time to adjust to GIP/GLP-1 receptor agonism. The SURMOUNT-1 protocol escalated to 5 mg after four weeks, with further 2.5 mg step-ups every four weeks as tolerated, up to a maximum of 15 mg.
My honest opinion: the people who try to rush this escalation almost always regret it. The nausea, the vomiting, the feeling of being hit by a truck. It's not a badge of honor. It's a sign you moved too fast. The four-week windows exist because they produced the best balance of efficacy and tolerability across thousands of trial participants. Faster is not better. It's just more miserable.
Building a Tolerability Plan Before You Need One
The time to plan for side effects is week zero, not the morning you wake up unable to keep water down.
A basic tolerability plan covers four things:
- Hydration targets. Set a daily ounce goal and track it. GLP-1 agonists slow gastric emptying, and dehydration makes nausea worse.
- Meal composition. Smaller, protein-forward meals. Fatty or greasy food becomes dramatically less appealing (and less tolerable) for most people on these medications.
- Fiber strategy. Constipation is common. A fiber supplement or deliberate dietary fiber can preempt the worst of it.
- Low threshold for messaging your prescriber. Decide in advance that you'll reach out at the first sign of persistent vomiting, severe nausea lasting more than 48 hours, or anything that feels wrong. The prescriber can adjust timing, suggest supportive medications, or slow the escalation. But only if you tell them.
The gap between knowing these things and doing them is where most people lose. A plan you actually follow beats a perfect protocol you abandon by week three.
Protecting Lean Mass (the Part Most People Skip)
Rapid weight loss on GLP-1 therapy doesn't discriminate perfectly between fat and muscle. Without deliberate intervention, a meaningful percentage of weight lost will be lean mass. That matters for metabolic health, bone density, functional strength, and long-term weight maintenance.
The countermeasures are well established:
- Protein intake: 1.2 to 1.6 grams per kilogram of reference body weight per day. This is more protein than most people eat by default, especially when appetite is suppressed.
- Resistance training: Two to three sessions per week. It doesn't need to be elaborate. Squats, presses, rows, deadlifts. The stimulus to keep muscle needs to be present while the caloric deficit is stripping away tissue.
Think of it like renovating a house while someone is simultaneously hauling away materials. If you don't flag which walls are load-bearing, the demolition crew won't know the difference. Protein and resistance training are how you flag the muscle as worth keeping.
Planning for the Long Horizon (Starting Now)
SURMOUNT-4 and STEP-4 both demonstrated the same uncomfortable truth: weight regain begins after discontinuation. In SURMOUNT-4, participants randomized to placebo after 36 weeks of tirzepatide regained roughly half their lost weight over the subsequent year. STEP-4 showed a similar pattern with semaglutide.
The right time to think about maintenance isn't when you hit your goal weight. It's the first week. What does your plan look like at month 12? Month 24? Is the expectation to stay on medication indefinitely, taper to a lower dose, or transition to lifestyle-only maintenance? These are conversations worth having early, when the decisions still feel abstract, because by the time they're urgent, you're making them under emotional pressure.
Across the GLP-1 class, the strongest predictor of long-term outcome is months on therapy at or near the maintenance dose. Everything else matters less than that.
Tracking What Actually Matters
A short weekly log beats memory every time. Five data points, recorded once a week:
- Dose (mg and units)
- Side effects (type and severity, 1 to 10 scale)
- Hydration (estimated daily intake)
- Protein (rough daily grams)
- One wellbeing metric (energy, mood, sleep quality, whatever feels most relevant to you)
This takes two minutes. It produces signal that a single office visit or telehealth check-in simply cannot replicate. When your prescriber asks "how have the last four weeks been?" you can answer with data instead of a vague impression colored by whatever happened yesterday.
Putting the Trial Numbers in Context
Trial averages compress enormous variance into a single number. SURMOUNT-1, for example, reported substantial differences in response within the same dose arm. Some people lost significantly more weight than the group mean; others lost less. That's the normal pattern across every GLP-1 trial published to date.
Real-world cohorts add even more variance, mostly from differences in adherence, diet, activity, and baseline metabolic status. The right way to think about published results: useful anchor, not guaranteed destination.
Every published GLP-1 weight-loss trial included a lifestyle component. SURMOUNT-1, STEP 1, and the SURPASS series all bundled calorie guidance and physical-activity recommendations with the pharmacotherapy. The headline results reflect medication plus lifestyle working together. The medication doesn't work in isolation in the real world either. Patients who treat it as one input among several (not the entire plan) tend to land closer to those published averages.
Protein intake, resistance training, sleep quality, and hydration are the four most commonly underweighted inputs. Each one is a small lift to implement and a substantial multiplier over months.
Frequently Asked Questions
Should I discuss 2.5 mg/mL dosing questions with my clinician?
Yes. Any question affecting how a prescription medication is dosed, stored, or administered is worth raising with your prescriber. This article is general education, not individualized clinical guidance.
What if I drew the wrong number of units last week?
Stop. Do not inject again. Contact your prescriber. If the medication has already been injected at the wrong dose, your prescriber will advise on next steps. Do not "make up" a dose without explicit instructions.
Does the unit count change if the pharmacy ships a different concentration?
Yes. The unit count is derived from the concentration. A new concentration means a new unit count, even if the milligram dose is the same. Read the label on every new shipment.
Can I use a different syringe than the one the pharmacy provided?
Use only the syringe size and type specified by your pharmacy. A U-100 insulin syringe is standard for the most common compounded GLP-1 concentrations. Substituting a different syringe changes the calibration and is a known source of dosing errors.
Is compounded tirzepatide FDA-approved?
No. Compounded tirzepatide is not an FDA-approved drug. The FDA does not review compounded medications for safety, effectiveness, or quality prior to dispensing. Compounded medications are dispensed under personalized prescriptions through state-licensed pharmacies when a prescriber determines a personalized formulation is clinically appropriate.
What's a quick way to double-check my dosing math?
Dose in mg ÷ concentration in mg/mL = volume in mL. Multiply volume by 100 to get units on a U-100 syringe. Do this calculation every time you receive a new vial. Write the unit count on a sticky note and attach it to the vial if that helps.
Continue the Series
Important Safety Information
This article is for educational purposes only and is not medical advice. Compounded tirzepatide and compounded semaglutide are not FDA-approved drugs. The FDA does not review compounded medications for safety, effectiveness, or quality before they are sold. Compounded medications should only be used when a licensed prescriber determines a personalized formulation is clinically appropriate. Do not start, stop, or modify any prescription medication without speaking with a licensed healthcare provider. If you experience symptoms of a serious reaction, including severe abdominal pain, signs of pancreatitis, vision changes, persistent vomiting, signs of an allergic reaction, or thoughts of self-harm, seek emergency care immediately.
FormBlends sells only compounded semaglutide and compounded tirzepatide through licensed U.S. pharmacies after a telehealth evaluation by an independent prescriber. Eligibility, pricing, and formulation are determined on a case-by-case basis.
About This Article
Written by Priya Mehta, PharmD (Clinical Pharmacist). Medically reviewed by Dr. Robert Yamada, MD (Board-Certified Endocrinology). FormBlends content is reviewed by licensed U.S. clinicians prior to publication. The clinical decisions described above are general education only and should not replace individualized advice from your own healthcare provider.